Literature DB >> 17298222

(Far) Outside the box: genomic approach to acute porphyria.

S Thunell1.   

Abstract

If I were living in Caucasus I would be writing fairy tales there Chekov, 1888 The question of the reasons for the extreme variation in morbidity among the gene carriers of acute porphyria and the great diversity of the precipitating factors are approached by the aid of a model of interacting genomic circuits. It is based on the current paradigm of the acute porphyric attack as a result of a toxic proximal overload of the enzyme-deficient heme-biosynthetic patway. Porphyrogenic influx of precursors is seen as a consequence of uncontrolled induction of its gate-keeping enzyme, ubiquitous 5-aminolevulinate synthase (ALAS1), due to attenuated post-translational control of the enzyme combined with activated gene transcription. Focus is directed on the genomic control of the master-regulator of ALAS1-transcription, the nuclear receptor pair constitutively active receptor (CAR) and pregnane xenobiotic receptor (PXR). On activation by their ligands, i.e. lipophilic drugs, solvents, alcohols, hormonal steroids and biocides, these DNA-binding proteins transform xenobiotic or steroid stimuli to coordinated activations of gene transcription-programs for ALAS1 and apo-cytochromes P450 (apo-CYPs), thus effecting the formation of xenobiotic-metabolizing cytochrome P450 enzymes. The potency of the CAR/PXR-transduction axis is enhanced by co-activators generated in at least four other genomic circuits, each triggered by different external and internal stimuli clinically experienced to be porphyrogenic, and each controlled by co-activating and co-repressing modulators. The expressions of the genes for CAR and PXR are thus augmented by binding glucocorticoid receptor (GR) activated by a steroid hormone, e.g, cortisol generated in fasting, infection or different forms of stress. The promotor regions of ALAS1 and apoCYPs contain binding sites for at least three co-activating transcription factors enhancing CAR/PXR transduction: i.e. the ligand-independent growth hormone (GH)-pulse controlled hepatocyte nuclear factor 4 (HNF4), the insulin-responsive forkhead box class O-(FOXO) protein pathway activated in stress and infection, and the proliferator-activated receptor gamma co-activator 1 alpha (PGC-1alpha) circuit responding to glucagon liberated in fasting. Many interactions and cross-talk take place within the tangle of genomic circuits that control ALAS1-transcription, which may explain the extreme inter- and intra-individual variability in morbidity in acute porphyria. Reasons for gender-differences are found in sex-dependent control of HPA- and GH-activity as well as in direct, or GR-mediated effects on CAR/PCR activation. Constitutional differences in individual porphyric morbidity may be discussed along lines of mutations or duplications of genes for co-activating or co-repressing nuclear proteins active at different levels within the circuits.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17298222     DOI: 10.33549/physiolres.930000.55.S2.43

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  6 in total

Review 1.  Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias.

Authors:  Stig Thunell; Erik Pomp; Atle Brun
Journal:  Br J Clin Pharmacol       Date:  2007-06-19       Impact factor: 4.335

2.  Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria.

Authors:  Pauline Harper; Staffan Wahlin
Journal:  Curr Treat Options Gastroenterol       Date:  2007-12

3.  The acute porphyrias: a diagnostic and therapeutic challenge in internal and emergency medicine.

Authors:  Paolo Ventura; Maria Domenica Cappellini; Emilio Rocchi
Journal:  Intern Emerg Med       Date:  2009-05-29       Impact factor: 3.397

4.  An Audit of the Use of Gonadorelin Analogues to Prevent Recurrent Acute Symptoms in Patients with Acute Porphyria in the United Kingdom.

Authors:  Danja Schulenburg-Brand; Tricia Gardiner; Simon Guppy; David C Rees; Penelope Stein; Julian Barth; M Felicity Stewart; Michael Badminton
Journal:  JIMD Rep       Date:  2017-02-21

5.  Genetic and Functional Evaluation of the Role of FOXO1 in Antituberculosis Drug-Induced Hepatotoxicity.

Authors:  Jingwei Zhang; Lin Jiao; Jiajia Song; Tao Wu; Hao Bai; Tangyuheng Liu; Zhenzhen Zhao; Xuejiao Hu; Binwu Ying
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-19       Impact factor: 2.629

6.  Adrenal hormonal imbalance in acute intermittent porphyria patients: results of a case control study.

Authors:  Oscar J Pozo; Josep Marcos; Andreu Fabregat; Rosa Ventura; Gregori Casals; Paula Aguilera; Jordi Segura; Jordi To-Figueras
Journal:  Orphanet J Rare Dis       Date:  2014-04-16       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.